SNDX
SyndaxยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
SNDX Profile
Syndax Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company that developing therapies for the treatment of resistant cancers
730 Third Avenue, 9th Floor, New York, New York 10017
--
Syndax Pharmaceuticals, Inc., was incorporated under the laws of the State of Delaware on October 11, 2005. The company is a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The company is developing revumenib, a potent, selective, small molecule inhibitor of menin-MLL binding interactions, for the treatment of KMT2A rearrangement or KMT2AR, also known as mixed-lineage leukemia rearrangement or MLLR, acute leukemia including acute lymphoblastic leukemia or ALL, and acute myeloid leukemia or AML, and necleophosmin 1, Also known as NPM 1, mutant AML.
